Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection

Purpose

We previously developed a multigene expression model of tumor radiation sensitivity index (RSI) with clinical validation in multiple independent cohorts (breast, rectal, esophageal, and head and neck patients). The purpose of this study was to assess differences between RSI scores in primary colon cancer and metastases.

Methods and Materials

Patients were identified from our institutional review board–approved prospective observational protocol. A total of 704 metastatic and 1362 primary lesions were obtained from a de-identified metadata pool. RSI was calculated using the previously published rank-based algorithm. An independent cohort of 29 lung or liver colon metastases treated with 60 Gy in 5 fractions stereotactic body radiation therapy (SBRT) was used for validation.

Results

The most common sites of metastases included liver (n=374; 53%), lung (n=116; 17%), and lymph nodes (n=40; 6%). Sixty percent of metastatic tumors, compared with 54% of primaries, were in the RSI radiation-resistant peak, suggesting metastatic tumors may be slightly more radiation resistant than primaries (P=.01). In contrast, when we analyzed metastases based on anatomical site, we uncovered large differences in RSI. The median RSIs for metastases in descending order of radiation resistance were ovary (0.48), abdomen (0.47), liver (0.43), brain (0.42), lung (0.32), and lymph nodes (0.31) (P<.0001). These findings were confirmed when the analysis was restricted to lesions from the same patient (n=139). In our independent cohort of treated lung and liver metastases, lung metastases had an improved local control rate compared to that in patients with liver metastases (2-year local control rate of 100% vs 73.0%, respectively; P=.026).

Conclusions

Assessment of radiation sensitivity between primary and metastatic tissues of colon cancer histology revealed significant differences based on anatomical location of metastases. These initial results warrant validation in a larger clinical cohort.

Introduction

Studies have shown long-term survival in patients treated for resection of limited metastatic disease 1, 2, 3. Similarly, aggressive treatment delivered to a single site of metastatic disease in the brain has shown improved overall survival (OS) 4, 5. Treatment of oligometastatic disease has become more common among radiation oncologists 6, 7, 8. Salama et al (9) reported on the treatment of 1 to 5 metastatic sites with stereotactic body radiation therapy (SBRT) to all known cancer sites with long-term OS reported (9). There are known biological differences between primary and metastatic lesions (10). Institutional reports have suggested a dose-response relationship with the treatment of SBRT in patients with lung and liver metastases 11, 12, 13.

Significant differences in radiation sensitivity of tumor types are believed to exist based on the α/β ratio of the cell survival curve. A tool to help in the selection of a dose and fractionation schedule for metastatic disease based on anatomical location may have large implications in the management of patients with oligometastatic disease. We have previously developed a multigene expression model of tumor radiation sensitivity (14). This model has been validated in multiple independent clinical cohorts including breast, rectal, esophageal, and head and neck cancers 14, 15. This model predicts a radiation sensitivity index (RSI) that is directly proportional to tumor radiation resistance (RSI: high index = radiation resistance). The purpose of this study was to assess differences between RSI in primary colon cancer and those in metastases, as well as differences between RSI in primary and metastatic colon cancer from the same patient. In addition, we validated the results in an independent clinical cohort of patients treated to sites of oligometastatic disease of colon primary.